Vor Biopharma (NYSE:VOR) Announces Stock Option Repricing

Vor Biopharma Inc. recently disclosed in an SEC filing on February 3, 2025, that its Board of Directors has greenlit a stock option repricing initiative. This move, effective immediately, entails a reduction in the exercise price of select outstanding options tailored to purchase shares of the company’s common stock. Under the repricing strategy, the exercise […]

Leave a Reply

Your email address will not be published.

Previous post Best Large Cap Stocks To Consider – February 08th
Next post Vincerx Pharma (NASDAQ: VINC) Modifies Terms of Business Combination with Oqory